CCM
CBAY

CTC Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

CTC Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$93.3K Buy
+10,700
New +$85.7K 0.2% 54

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CTC Capital Management's CBAY Position: Q1 2023 in Review

CTC Capital Management opened a new position in Cymabay Therapeutics (CBAY) in Q1 2023: 10,700 shares worth $93.3K. The stake represents 0.2% of the portfolio and ranks #54 among its holdings.

139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • CTC Capital Management held 10,700 shares of Cymabay Therapeutics worth $93.3K as of Q1 2023.
  • Cymabay Therapeutics was a new CTC Capital Management position in Q1 2023.
  • Cymabay Therapeutics made up 0.2% of CTC Capital Management's portfolio in Q1 2023, its #54 holding.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.